Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GJWCO
ADC Name
CA2975383C example19
Synonyms
CA2975383C example19
   Click to Show/Hide
Organization
SORRENTO THERAPEUTICS, INC.
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
undisclosed
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Tubulin inhibitor C
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random coupling of lysine
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.156
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.193
nM
CVCL_1259
Breast ductal carcinoma
Half Maximal Effective Concentration (EC50) 
0.232
nM
CVCL_0179
Invasive breast carcinoma
Half Maximal Effective Concentration (EC50) 
0.34
nM
CVCL_0532
Ovarian serous adenocarcinoma
Half Maximal Effective Concentration (EC50) 
3.946
nM
CVCL_0418
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.156 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.193 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.232 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.34 nM Positive HER2 expression (HER2 +++/++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Ovarian serous adenocarcinoma SKOV-3 cells CVCL_0532
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 3.946 nM Moderate XXX expression (XXX++)
Method Description
This example provides the results of EC50 assays of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody.
In Vitro Model Breast adenocarcinoma MDA-MB-453 cells CVCL_0418
References
Ref 1 Antibody drug conjugates comprising dolastatin derivatives